1. Moberg CL, Cohn
ZA. Rene Jules Dubos. Sci Am 1991; 264: 66-74.
2. Feynman R. Surely
you must be joking, Mr. Feynman. Bantam, New York, 1985.
3. Centers for Disease
Control and Prevention. U.S. HIV and AIDS cases reported through December
1995. HIV/AIDS Surveillance Report 1995; 7: 1-39.
4. Institute of Medicine,
National Academy of Sciences. Confronting AIDS. National Academy Press,
Washington, DC, 1986.
5. Institute of Medicine.
Confronting AIDS—Update 1988. National Academy Press, Washington, DC, 1988.
6. Adams J. AIDS:
The HIV Myth. St. Martin’s Press, New York, 1989.
7. Hodgkinson N.
AIDS: the failure of contemporary science. Fourth Estate, London, UK, 1996.
8. Rothman S. Remarks
on sex, age and racial distribution of Kaposi’s sarcoma and on possible
pathogenic factors. Acta Unio Int Contra Cancrum 1962; 18:
326.
9. Oettle AG. Geographical
and racial differences in the frequencies of Kaposi’s sarcoma as evidence
of environmental or genetic causes. Acta Unio Int Contra Cancrum
1962; 18: 330-362.
10. Springer Verlag.
50 Jahre Springer - 50 Jahre Zeitzeuge. Axel Springer Verlag, Hamburg,
1996.
11. Duesberg P.
Inventing the AIDS Virus. Regnery Publishing Inc., Washington, 1996.
12. Horton R. Truth and heresy about
AIDS. The New York Review 1996; 43: 14, 16-20, May 23.
13. Institute of Medicine. Confronting
AIDS. National Academy Press, Washington, DC, 1986.
14. Anonymous (eds.) The relationship
between Human Immunodeficiency Virus and the Acquired Immunodeficiency
Syndrome (1996), National Institute for Allergy & Infectious Diseases,
Bethesda, MD, .
15. Altman LK. Researchers believe
AIDS virus is found. New York Times (New York) 1984: C1, C3, April
24.
16. Cohen J. The Duesberg Phenomenon.
Science 1994; 266: 1642-1649.
17. Centers for Disease Control and
Prevention. 1993 revised classification system for HIV infection and expanded
surveillance case definition for AIDS among adolescents and adults. Morb
Mort Weekly Rep 1992; 41(No. RR17): 1-19.
18. Duesberg PH. Infectious AIDS
stretching the germ theory beyond its limits. Int Arch Allergy Immunol
1994; 103: 131-142.
19. Auerbach DM, Darrow WW, Jaffe
HW, Curran JW. Cluster of cases of the Acquired Immune Deficiency Syndrome
patients linked by sexual contact. Am J Med 1984; 76: 487-492.
20. Bregman DJ, Langmuir AD. Farr’s
law applied to AIDS projections. J Am Med Assoc 1990; 263:
50-57.
21. National Commission on AIDS.
The Twin Epidemics of Substance Use and HIV. July 1991;
22. Duesberg P. Duesberg’s questions.
C&EN 1996; 4, 40.
23. Duesberg P. Is HIV the cause
of AIDS? (letter). Lancet 1995; 346: 1371-1372.
24. Duesberg P. Foreign-protein-mediated
immunodeficiency in hemophiliacs with and without HIV. Genetica
1995; 95: 51-70.
25. Duesberg P. How much longer can
we afford the AIDS virus monopoly?, in AIDS: virus or drug-induced?,
P. Duesberg (eds.) Kluwer, Dordrecht, Netherlands, 1996; 241-270.
26. Duesberg PH. AIDS acquired by
drug consumption and other noncontagious risk factors. Pharmacology
& Therapeutics 1992; 55: 201-277.
27. Drotman DP, Peterman TA, Friedman-Kien
AE. Kaposi’s sarcoma. How can epidemiology help find the cause? Dermatoepidemiology
1995; 13: 575-582.
28. Bennett A, Sharpe A. AIDS fight
is skewed by federal campaign exaggerating risks. Wall Street Journal
1996: 1, A6, May 1.
29. Krieger L. 1 in 300 U.S. adults
infected, says report. SF Examiner (San Francisco) 1996: A8, July
7.
30. Simmonds P, Balfe P, Peutherer
JF, Ludlam CA, Bishop JO, Leigh-Brown AJ. Human immunodeficiency virus-infected
individuals contain provirus in small numbers of peripheral mononuclear
cells and at low copy numbers. J Virol 1990; 64: 864-872.
31. Duesberg PH, Bialy H. Duesberg
and the right of reply according to Maddox-Nature, in AIDS: virus- or
drug induced?, P. H. Duesberg (eds.) Kluwer Academic Publishers, Dordrecht/Boston/London,
1996; 111-125.
32. Craddock M. HIV: Science by press
conference, in AIDS: virus- or drug induced?, (eds.) Kluwer, Dordrecht,
Netherland, 1996; 127-130.
33. Ho DD, Neumann AU, Perelson AS,
Chen W, Leonard JM, Markowitz M. Rapid Turnover of Plasma Virions and CD4
Lymphocytes in HIV-1 Infection. Nature 1995; 373: 123-126.
34. Maddox J. Duesberg and the new
view of HIV. Nature 1995; 373: 189.
35. Duesberg P, Horton R. The AIDS
Heresy: an exchange. The New York Review 1996; 43: 51, August 8.
36. Beral V, Peterman TA, Berkelman
RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted
infection? Lancet 1990; 335: 123-128.
37. Haverkos HW, Drotman DP, Hanson
D. Surveillance for AIDS-related Kaposi’s sarcoma (KS): update. NIDA/CDC,
Rockville, MD/Atlanta, GA 1994; May.
38. Duesberg P. Commentary: non-HIV
hypotheses must be studied more carefully. BMJ 1996; 312:
210-211.
39. Lockemann U, Wischhusen F, Pueschel
K, et al. Vergleich der HIV-1-Praevalenz bei Drogentodesfaellen in Deutschland
sowie in verschiedenen europaeischen Grosstaedten (Stand: 31. 12. 1993).
AIDS Forschung 1995; 10: 253-256.
40. Brettle RP. Clinical features
of drug use and drug use related to HIV. Int J STD & AIDS 1996;
7: 151-165.
41. Hayes T, Altman R, Akili-Obika
A, Buehler JW, Costa SJ, Beil JK, Moore LG, Massey JW, Williams NM. HIV-related
deaths from selected infectious diseases among persons without AIDS in
New Jersey. Journal of Acquired Immune Deficiency Syndromes 1994;
7: 1074-1078.
42. Kitange HM, Machibya H, Black
J, Mtasiwa DM, Masuki G, Whiting D, Unwin N, Moshiro C, Klima PM, Lewanga
M, Alberti KGMM, McLarty D, for adult morbidity and mortality project.
Outlook for survivors of childhood in sub-Saharan Africa: adult mortality
in Tanzania. BMJ 1996; 312: 216-220.
43. Peterman TA, Stoneburner RL,
Allen JR, Jaffe HW, Curran JW. Risk of human immunodeficiency virus transmission
from heterosexual adults with transfusion-associated infections. JAMA
1988; 259: 55-58.
44. Jacquez JA, Koopman JS, Simon
CP, Longini Jr. IM. Role of the primary infection in epidemics of HIV infection
in gay chorts. J Acquired Immune Deficiency Syndromes 1994; 7:
1169-1184.
45. Connor EM, Sperling RS, Gelber
R, Kiselev P, Scott G, O’Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson
RL, Jimenez E, O’Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R,
Elkins M, Moye J, Stratton P, Balsley J, Pediatric AIDS Clinical Trials
Group Protocol 076 Study Group. Reduction of Maternal-Infant Transmission
of Human Immunodeficiency Virus Type 1 With Zidovudine Treatment. New
Engl J Med 1994; 331: 1173-1180.
46. Duesberg PH. Retroviruses as
carcinogens and pathogens: expectations and reality. Cancer Res
1987; 47: 1199-1220.
47. Duesberg PH. HIV and AIDS. Science
1993; 260: 1705.
48. Duesberg PH. The HIV gap in national
AIDS statistics. Biotechnology 1993; 11: 955-956.
49. Cone RW, Hackman RC, Huang M-LW,
Bowden RA, Meyers JD, Metcalf M, Zeh J, Ashley R, Corey L. Human herpesvirus
6 in lung tissue from patients with pneumonia after bone marrow transplantation.
NEnglJMed 1993; 329: 156-161.
50. Mims C, White DO. Viral Pathogenesis
and Immunology. Blackwell Scientific Publications, Oxford, 1984.
51. Drug Strategies. Keeping score;
What We Are Getting for Our Federal Drug Control Dollars. Drug Strategies,
Washington DC, 1995.
52. Bureau of Justice Statistics.
Drugs, crime, and the justice system. U.S. Dept. of Justice, Washington
DC, 1992.
53. Clinton W, The White House. The
National Drug Control Strategy: 1996. The White House, Washington DC, 1996.
54. Courtwright DT. Dark Paradise:
opiate addiction in America before 1940. Harvard University Press, Cambridge,
MA, 1982.
55. Jonnes J. Hep-cats, narcs, and
pipe dreams. Scribner, New York, 1996.
56. Haverkos HW, Dougherty J. Health
hazards of nitrite inhalants. Am J Med 1988; 84: 479-482.
57. Siegel R. New pattenrs of cocaine
use: changing doses and routes, in Cocaine use in America: epidemiologic
and clinical perspectives, N. Kozel and E. Adams (eds.) NIDA Research
Monographs, Washington DC, 1985;
58. Schuster C. Cocaine use in America:
epidemiological and clinical perspectives, in NIDA Research Monograph
Series, NIDA US Department HHS (eds.) US Dept. HHS, 1985; v.
59. Kozel NJ, Adams EH. Epidemiology
of drug abuse: An overview. Science 1986; 234: 970-974.
60. Meddis SV. Heroin use said to
near crisis level. USA Today (Arlington) 1994: 1, 3A, May 25.
61. U.S. Department of Health &
Human Services. Annual Medical Examiner data. Data from the Drug Abuse
Warning Network (DAWN) 1994; 1-82, 1994.
62. Office of National Drug Control
Policy. Drugs & Crime Data. Drugs & Crime Clearinghouse
1996; July 1996.
63. Perlman D. Cocaine Emergencies
Hit Record. SF Chronicle (San Francisco) 1996: A1, A9, May 1.
64. Bureau of Justice Statistics
(eds.) Catalog of Federal Publications on Illegal Drug and Alcohol Abuse
(1991), U.S. Department of Justice, Washington D.C., .
65. Flanagan TJ, Maguire K. Sourcebook
of Criminal Justice Statistics (1989)—Bureau of Justice Statistics NCJ-124224.
U.S. Department of Justice, U.S. Government Printing Office, Washington,
DC, 1989.
66. Anderson W. Drug Smuggling. U.
S. General Accounting Office, Washington, DC, 1987.
67. Schnoll SH, Karrigan J, Kitchen
SB, Daghestani A, Hansen T. Characteristics of cocaine abusers presenting
for treatment, in Cocaine use in America: epidemiologic and clinical
perspectives, NIDA US Dept. HHS (eds.) US Dept. HHS, 1985; 171-181.
68. Gettman J. Heroin Returning to
Center Stage. High Times 1994; 23, December.
69. Smith RJ. U.S. Is Losing War
on Drugs, Analysts Say. San Francisco Chronicle (SF) 1995: A1, A9,
July 10.
70. Evenson L, Whiting S. Heroin’s
in Fashion--and Death Statistics Prove It. San Francisco Chronicle
(San Francisco) 1996: A1-A8, Jul 30.
71. Sadownick D. Kneeling at the
Crystal Cathedral. Genre 1994; 40-45, 86-90, December/January 1994.
72. Rotello G. A deal with the devil.
The Advocate 1996; 96, October, 15.
73. Russell S. ‘Speed’ Hospitalizations
Soar. SF Chronicle (San Francisco) 1996: A13, A15, July 2.
74. Drug Strategies. Keeping Score.
Keeping Score 1996; 1-33.
75. Wallace B. ‘Speed’ Abusers Need
More and More. SF Chronicle (San Francisco) 1996: A2, May 31.
76. Mann C. Poppers ... high time
to think again. Continuum 1995; 3: 10,
77. Young I. Hell Bent ... or Heavenly
Scent? Continuum 1995; 3: 22-25,
78. Bethell T. AIDS and Poppers,
in AIDS: Virus- or Drug Induced?, P. Duesberg (eds.) Kluwer Academic
Publishers, Dordrecht, 1996; 315-323.
79. San Francisco Department of Public
Health, Lesbian & Gay Substance Abuse Planning Group. Lesbian, Gay
and Bisexual Substance Abuse Needs Assessment. 1991, August;
80. Ascher MS, Sheppard HW, Winkelstein
Jr W, Vittinghoff E. Does drug use cause AIDS? Nature 1993; 362:
103-104.
81. Haverkos HW, Drotman DP. NIDA
technical review: nitrite inhalants. Biomedicine & Pharmacotherapy
1996; 50: 228-230.
82. Fietz M. Haschisch an der Spitze;
SPD: Mildere Strafen fuer Drogenhaendler. Die Welt 1997; pp. 1,2,
Jan. 8.
83. Rauschgiftbilanz 1994. Starke
Nachfrage nach synthetischen Drogen. Deutsches Aerzteblatt 1995;
92: C-422.
84. AIDS-Forschung. AIDS Zentrum
im Robert Koch Institut. 120. Bericht des AIDS-Zentrums im Robert-Koch-Institut
über aktuelle epidemiologische Daten. AIDS-Forschung 1996;
11: 47-56.
85. U.S. Department of Health &
Human Services. Annual emergency department data 1993. Data from the
Drug Abuse Warning Network (DAWN) 1993; 81-110,
86. Stoneburner RL, Des Jarlais DC,
Benezra D, Gorelkin L, Sotheran JL, Friedman SR, Schultz S, Marmor M, Mildvan
D, Maslansky R. A larger spectrum of severe HIV-I-related disease in intravenous
drug users in New York City. Science 1988; 242: 916-919.
87. Alcabes P, Schoenbaum EE, Klein
RS. Correlates of the rate of decline of CD4+ lymphocytes among injection
drug users infected with the human immunodeficiency virus. American
Journal of Epidemiology 1993; 137: 989-1000.
88. Alcabes P, Munoz A, Vlahov D,
Friedland G. Maturity of human immunodeficiency virus infection and incubation
period of acquired immunodeficiency syndrome in injecting drug users. AIDS
Epidemiology and Pharmacology 1994; 4: 17-26.
89. Des Jarlais D, Friedman S, Marmor
M, Cohen H, Mildvan D, Yancovitz S, Mathur U, El-Sadr W, Spira TJ, Garber
J. Development of AIDS, HIV seroconversion, and potential cofactors for
T4 cell loss in a cohort of intravenous drug users. AIDS 1987; 1:
105-111.
90. Novick DM, Ochshorn M, Ghali
V, Croxson TS, Mercer WD, Chiorazzi N, Kreek MJ. Natural killer cell activity
and lymphocyte subsets in parenteral heroin abusers and long-term methadone
maintenance patients. The Journal of Pharmacologyt and Experimental
Therapeutics 1989; 250: 606-610.
91. Margolick JB, Munoz A, Vlahov
D, Solomon L, Astemborski J, Cohn S, Nelson KE. Changes in T-lymphocyte
subsets in intravenous drug users with HIV-1 infection. Journal of the
American Medical Association 1992; 267: 1631-1636.
92. Margolick JB, Munoz A, Vlahov
D, Astemborski J, Solomon L, He X-Y, Nelson KE, Saah AJ. Direct comparison
of the relationship between clinical outcome and change in CD4+ lymphocytes
in human immunodeficiency virus-positive homosexual men and injecting drug
users. Archives of Internal Medicine 1994; 154: 869-875.
93. Galli M, Lazzarin A, Saracco
A, Balotta C, Castagna A, Negri C, Ridolfo AL, Uberti-Foppa C, Corbellino
M, Moroni M. Clinical and immunological aspects of HIV infection in drug
addicts. Clinical Immunology and Immunopathology 1989; 50:
S166-S176.
94. Mirken B. Everything you always
wanted to know about poppers; the gay drug is still here despite a ban,
and so is the controversy. San Francisco Frontiers Newsmagazine
1995; 14: 16-19, July 20.
95. St. Angelo M. Duesberg’s Questions
About HIV/AIDS Merit Answers. Windy City Times 1996: 12, April 11.
96. Lauritsen J. NIDA meeting calls
for research into the poppers-Kaposi’s sarcoma connection, in AIDS:
Virus- or Drug Induced?, P. H. Duesberg (eds.) Kluwer Academic Publishers,
Dordrecht, 1996; 325-330.
97. Lauritsen J. The AIDS War. Asklepios
(Pagan Press), New York, 1993.
98. Shilts R. And the Band Played
On. St. Martin’s Press, New York, 1987.
99. Ineichen H. Ausgeschnüffelt?
aK (Switzerland) 1996; 5: 18-19, October November.
100. Ostrow DG. Substance abuse and
HIV infection. Psychiatric Manifestations of HIV Disease 1994; 17:
69-89.
101. Buchbinder
SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection
without immunologic progression. AIDS 1994; 8: 1123-1128.
102. Veugelers PJ, Page KA, Tindall
B, Schechter MT, Moss AR, Winkelstein WW, Cooper DA, Craib KJP, Charlebois
E, Coutinho RA, Van Griensven GJP. Determinants of HIV disease progression
among homsexual men registered in the tricontinental seroconverter study.
American Journal of Epidemiology 1994; 140: 747-758.
103. Kaslow RA, Blackwelder WC, Ostrow
DG, Yerg D, Palenicek J, Coulson AH, Valdiserri RO. No evidence for a role
of alcohol or other psychoactive drugs in accelerating immunodeficiency
in HIV-1-positive individuals. J Am Med Assoc 1989; 261:
3424-3429.
104. Ostrow DG, Beltran ED, Joseph
JG, DiFranceisco W, Wesch J, Chmiel JS. Recreational drugs and sexual behavior
in the Chicago MACS/CCS cohort of homosexually active men. Journal of
Substance Abuse 1993; 5: 311-325.
105. Schechter MT, Craib KJP, Montaner
JSG, Le TN, O'Shaughnessy MV, Gelmon KA. Aetiology of AIDS. Lancet
1993; 341: 1222-1223.
106. Lau RKW, Jenkins P, Caun K,
Forster SM, Weber JN, McManus TJ, Harris JRW, Jeffries DJ, Pinching AJ.
Trends in sexual behaviour in a cohort of homosexual men: a 7 year prospective
study. International Journal of STD & AIDS 1992; 3: 267-272.
107. Gibbons J. Drugs & Us. Gay
Times (London) 1996; 17-37, September.
108. McManus TJ, Starrett LA, Harris
JRW. Amyl Nitrite Use by Homosexuals. Lancet 1982; i: 503.
109. Lauritsen J. NIH reconsiders
nitrites' link to AIDS. Biotechnology 1994; 12: 762-763.
110. Haverkos HW, Drotman DP. NIDA
Technical Review: Nitrite Inhalants. NIDA, Washington, D.C & CDC,
Atlanta, GA 1995; unpublished.
111. Jaffe HW, Choi K, Thomas PA,
Haverkos HW, Auerbach DM, Guinan ME, Rogers MF, Spira TJ, Darrow WW, Kramer
MA, Friedman SM, Monroe JM, Friedman-Kien AE, Laubenstein LJ, Marmor M,
Safai B, Dritz SK, Crispi SJ, Fannin SL, Orkwis JP, Kelter A, Rushing WR,
Thacker SB, Curran JW. National case-control study of Kaposi's sarcoma
and Pneumocystis carinii pneumonia in homosexual men: Part 1, Epidemiologic
results. Ann Intern Med 1983; 99: 145-151.
112. Darrow WW, Echenberg DF, Jaffe
HW, O'Malley PM, Byers RH, Getchell JP, Curran JW. Risk factors for human
immunodeficiency virus (HIV) infections in homosexual men. Am J Publ
Health 1987; 77: 479-483.
113. Lifson AR, Darrow WW, Hessol
NA, O'Malley PM, Barnhart JL, Jaffe HW, Rutherford GW. Kaposi's sarcoma
in a cohort of homosexual and bisexual men: epidemiology and analysis for
cofactors. Am J Epidemiol 1990; 131: 221-231.
114. Duesberg PH. Can epidemiology
determine whether drugs or HIV cause AIDS? AIDS-Forschung 1993;
12: 627-635.
115. Ellison BJ, Downey AB, Duesberg
PH. HIV as a surrogate marker for drug-use: a re-analysis of the San Francisco
Men's Health Study, in AIDS: virus- or drug induced?, P. H. Duesberg
(eds.) Kluwer Academic Publishers, Dordrecht, The Netherlands, 1996; 97-104.
116. Schechter MT, Craib KJP, Gelmon
KA, Montaner JSG, Le TN, O'Shaughnessy MV. HIV-1 and the aetiology of AIDS.
Lancet 1993; 341: 658-659.
117. Bacellar H, Munoz A, Miller
EN, Cohen BA, Besley D, Selnes OA, Becker JT, McArthur JC. Temporal trends
in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS
Cohort Study, 1985-1992. Neurology 1994; 44: 1892-1900.
118. Wilson JM, Kalasinsky KS, Levey
AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW,
Kish SJ. Striatal dopamine nerve terminal markers in human, chronic metamphetamine
users. Nature Medicine 1996; 2: 699-703.
119. Achard C, Bernard H, Gagneux
C. Action de la morphine sur les proprietes leucocytaires; leuco-diagnostic
du morphinisme. Bulletin et Memoires de la Societe Medicale des Hopitaux
de Paris 1909; 28, 3rd Series: 958-966.
120. Pillari G, Narus J. Physical
effects of heroin addiction. Am J Nursing 1973; 73: 2105-2109.
121. Lerner WD. Cocaine abuse and
acquired immunodeficiency syndrome: tale of two epidemics. Am J Med
1989; 87: 661-663.
122. Layon J, Idris A, Warzynski
M, Sherer R, Brauner D, Patch O, McCulley D, Orris P. Altered T-lymphocyte
subsets in hospitalized intravenous drug abusers. Arch Intern Med
1984; 144: 1376-1380.
123. Larrat PE, Zierler S. Entangled
epidemics: cocaine use and HIV disease. J Psychoactive drugs 1993;
25: 207-221.
124. Pillai R, Nair BS, Watson RR.
AIDS, drugs of abuse and the immune system: a complex immunotoxicological
network. Arch Toxicol 1991; 65: 609-617.
125. Mientjes GHC, van Ameijden EJC,
Weigel HM, van den Hoek JAR, Countinho RA. Clinical symptoms associated
with seroconversion for HIV-1 among misusers of intravenous drugs: comparison
with homosexual seroconverters and infected and non-infected intravenous
drug misusers. BMJ 1993; 306: 371-373.
126. Wesson D, Smith D. Cocaine:
treatment perspectives, in Cocaine Use in America: epidemiologic and
clinical perspectives, N. Kozel and E. Adams (eds.) NIDA US Dept. HHS,
Washington, DC, 1985;
127. Muñoz A, Vlahov D, Solomon
L, Margolick JB, Bareta JC, Cohn S, Astemborski J, Nelson KE. Prognostic
indicators for development of AIDS among intranvenous drug users. JAIDS
1992; 5: 694-700.
128. Clair DA. Drug treatment specialist
of the Federal Bureau of Prisons, Greenville IL. personal communication
August 1996;
129. Weil A, Rosen W. Chocolate and
morphine. Houghton Mifflin Co., Boston, 1983.
130. Haverkos HW, Dougherty JA (eds.)
Health Hazards of Nitrite Inhalants (1988), US. Dept. Health &
Human Services, Washington, DC, .
131. Dax EM, Nagel JE, Lange WR,
Adler WH, Jaffe JH. Effects of nitrites on the immune system of humans,
in Health hazards of nitrite inhalants, H. W. Haverkos and J. A.
Dougherty (eds.) Dept. Health & Human Services, Washington, DC, 1988;
75-79.
132. Goedert JJ, Neuland CY, Wallen
WC, Greene MH, Mann DL, Murray C, Strong DM, Fraumeni JF, Jr., Blattner
WA. Amyl nitrite may alter T lymphocytes in homosexual men. Lancet
1982; i: 412-416.
133. Nieman RB, Fleming J, Coker
RJ, Harris JR, Mitchell DM. The effect of cigarette smoking on the development
of AIDS in HIV-1-seropositive individuals. AIDS 1993; 7:
705-710.
134. Lewis RJS. Food additives handbook.
Van Nostrand Reinhold, New York, NY 10003, 1989.
135. Winter R. A consumer's dictionary
of food additives. Crown Publishers, Inc., New York, NY 10022, 1989.
136. Mirvish SS, Williamson J, Babcook
D, Sheng-Chong C. Mutagenicity of iso-butyl nitrite vapor in the Ames test
and some relevant chemical properties, including the reaction of iso-butyl
nitrite with phosphate. Environmental and Molecular Mutagenesis
1993; 21: 247-252.
137. National Research Council. Diet,
nutrition, and cancer. National Acad. Press, Washington, D.C., 1982.
138. Newell GR, Mansell PWA, Spitz
MR, Reuben JM, Hersh EM. Volatile nitrites: Use and adverse effects related
to the current epidemic of the acquired immune deficiency syndrome. Am
J Med 1985; 78: 811-816.
139. Cox GD. County health panel
urges 'poppers' ban, cites AIDS link. The Los Angeles Daily Journal
(Los Angeles) 1986: Section II, p.1, Mar. 24.
140. Haverkos HW. Nitrite inhalant
abuse and AIDS-related Kaposi's sarcoma. JAIDS 1990; 3: Supplement
1, S47-S50.
141. Ratajczak HV, Thomas PT, House
RV, Gaworski CL, Sherwood RL, Luster MI, Hagen KL, Abdo K, Jackson CD,
Roycroft J, Aranyi C. Local versus Systemic Immunotoxicity of Isobutyl
Nitrite Following Subchronic Inhalation Exposure of Female B6C3F1 Mice.
Fundamental and Applied Toxicology 1995; 27: 177-184.
142. Pink Paper. Shops on their guard
after poppers sale legal setback. The Pink Paper (London) 1996:
June 28.
143. Seligmann M, Chess L, Fahey
JL, Fauci AS, Lachmann PJ, L'Age-Stehr J, Ngu J, Pinching AJ, Rosen FS,
Spira TJ, Wybran J. AIDS—an immunologic reevaluation. N Engl J Med
1984; 311: 1286-1292.
144. Lauritsen J, Wilson H. Death
Rush, Poppers and AIDS. Pagan Press, New York, 1986.
145. Moss AR. AIDS and intravenous
drug use: the real heterosexual epidemic. Br Med J 1987; 294:
389-390.
146. Kolata G. New picture of who
will get AIDS is dominated by addicts. New York Times (New York)
1995: Sect. C, p3, February 28.
147. Furman PA, Fyfe JA, St Clair
M, Weinhold K, Rideout JL, Freeman GA, Nusinoff-Lehrman S, Bolognesi DP,
Broder S, Mitsuya H, Barry DW. Phosphorylation of 3'-azido-3'-deoxythymidine
and selective interaction of the 5'-triphosphate with human immunodeficiency
virus reverse transcriptase. PNAS 1986; 83: 8333-8337.
148. Fischl MA, Richman DD, Grieco
MH, Gottlieb MS, Volberding PA, Laskin OL, Leedon JM, Groopman JE, Mildvan
D, Schooley RT, Jackson GG, Durack DT, King D, the AZT Collaborative Working
Group. The efficacy of azidothymidine (AZT) in the treatment of patients
with AIDS and AIDS-related complex. N Engl J Med 1987; 317:
185-191.
149. Kolata G. Imminent marketing
of AZT raises problems; Marrow suppression hampers AZT use in AIDS victims.
Science 1987; 235: 1462-1463.
150. Kramer L. A good news/bad new
AIDS joke. New York Times (New York) 1996: 26, Sunday, July 14.
151. Nussbaum B. Good Intentions:
How Big Business, Politics, and Medicine are Corrupting the Fight Against
AIDS. Atlantic Monthly Press, New York, 1990.
152. Physicians' Desk Reference.
Retrovir. Medical Economics Co., Orandell, NJ, 1994.
153. Mansuri MM, Hitchcock MJM, Buroker
RA, Bregman CL, Ghazzouli I, Desiderio JV, Starrett JE, Sterzycki RZ, Martin
JC. Comparison of in vitro biological properties and mouse toxicities of
three thymidine analogs active against human immunodeficiency virus. Antimicrobial
Agents and Chemotherapy 1990; 34: 637-641.
154. Lemaître M, Guetard D,
Henin Y, Montagnier L, Zerial A. Protective activity of tetracycline analogs
against the cytopathic effect of the human immunodeficiency viruses in
CEM cells. Res Virol 1990; 141: 5-16.
155. Avramis VI, Markson W, Jackson
RL, Gomperts E. Biochemical pharmacology of zidovudine in human T-lymphoblastoid
cells (CEM). AIDS 1989; 3: 417-422.
156. Sommadossi J-P, Zhu Z, Carlisie
R, Xie M-Y, Weidner DA, El Kouni MH. Novel pharmacological approaches to
the treatment of AIDS and potential use of uridine phosphorylase inhibitors,
in Advances in Chemotherapy of AIDS, R. B. Diasio and J.-P. Sommadossi
(eds.) Pergamon Press Inc., New York, 1990; 63-73.
157. Inoue T, Tsushita K, Itoh T,
Ogura M, Hotta T, Saneyoshi M, Yoshida S, Saitoh H, Tomoda Y, Nagai Y.
In vitro bone marrow toxicity of nucleoside analog against human immunodeficiency
virus. Antimicrob Agents Chemother 1989; 33: 576-579.
158. Gogu SR, Beckman BS, Agrawal
KC. Anti-HIV drugs: Comparative toxicities in murine fetal liver and bone
marrow erythroid progenitor cells. Life Sci 1989; 45: iii-vii.
159. Chiu D, Duesberg P. The Toxicity
of Azidothymidine (AZT) on Human and Animal Cells in Culture at Concentrations
Used for Antiviral Therapy. Genetica 1995; 95: 103-109.
160. Seligmann M, Warrell DA, Aboulker
J-P, Carbon C, Darbyshire JH, Dormont J, Eschwege E, Girling DJ, James
DR, Levy J-P, Peto PTA, Schwarz D, Stone AB, Weller IVD, Withnall R, Gelmon
K, Lafon E, Swart AM, Aber VR, Babiker AG, Lhoro S, Nunn AJ, Vray M. Concorde:
MRC/ANRS randomised double-blind controlled trial of immediate and deferred
zidovudine in symptom-free HIV infection. Lancet 1994; 343:
871-881.
161. Volberding PA, Lagakos SW, Koch
MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Jr., Reichman RC, Bartlett
JA, Hirsch MS, Murphy RL, Hardy WD, Soeiro R, Fischl MA, Bartlett JG, Merigan
TC, Hyslop NE, Richman DD, Valentine FT, Corey L, the AIDS Clinical Trial
Group of the National Insitute of Allergy and Infectious Disease. Zidovudine
in asymptomatic human immunodeficiency virus infection: A controlled trial
in persons with fewer than 500 CD4-positive cells per cubic millimeter.
N Engl J Med 1990; 322: 941-949.
162. Mir N, Costello C. Zidovudine
and bone marrow. Lancet 1988; ii: 1195-1196.
163. Dournon E, Matheron S, Rozenbaum
W, Gharakhanian S, Michon C, Girard PM, Perrone C, Salmon D, DeTruchis
P, Leport C, the Claude Bernard Hospital AZT Study Group. Effects of zidovudine
in 365 consecutive patients with AIDS or AIDS-related complex. Lancet
1988; ii: 1297-1302.
164. van Leeuwen R, van den Hurk
PJ, Jöbis GJ, van der Wouw PA, Reiss P, Eeftinck Schattenkerk JKM,
Danner SA, Lange JMA. Failure to maintain high-dose treatment regimens
during long-term use of zidovudine in patients with symptomatic human immunodeficiency
virus type 1 infection. Genitourin Med 1990; 66: 418-422.
165. Swanson CE, Cooper DA, the Australian
Zidovudine Study Group. Factors influencing outcome of treatment with zidovudine
of patients with AIDS in Australia. AIDS 1990; 4: 749-757.
166. Hamilton JD, Hartigan PM, Simberkoff
MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL,
Gordin FM, the Veterans Affairs Cooperative Study Group on AIDS Treatment.
A controlled trial of early versus late treatment with zidovudine in symptomatic
human immunodeficiency virus infection. N Engl J Med 1992; 326:
437-443.
167. Horwitz JP, Chua J, Noel M.
Nucleosides.V. The monomesylates of 1-(2'-deoxy-beta-D-lyxofuranosyl)thymidine.
J Org Chem 1964; 29: 2076.
168. Schnittman SM, Psallidopoulos
MC, Lane HC, Thompson L, Baseler M, Massari F, Fox CH, Salzman NP, Fauci
A. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains
expression of CD4. Science 1989; 245: 305-308.
169. Duesberg P, Bialy H. Duesberg
and the Right of Reply According to Maddox - Nature, in AIDS: Infectious
or Not?, P. Duesberg (eds.) Kluwer, Dordrecht, 1995;
170. Ascher MS, Sheppard HW, Anderson
RW, Krowka JF, Bremermann HJ. Paradox remains. Nature 1995; 375:
196.
171. Lauritsen J. Poison by Prescription—The
AZT Story. Asklepios Press, New York, 1990.
172. Wyatt EA. Rushing to Judgement.
Barron's 1994; 23-27, August, 15.
173. Hall CT. AIDS advances boost
drugmaker. San Francisco Chronicle (San Francisco) 1996: E1-E2,
August 1.
174. Day M. Hype, hope and HIV. New
Scientist 1996; 151: 28-31.
175. Rasnick D. Inhibitors of HIV
protease useless against AIDS because HIV doesn't cause AIDS. Reappraising
AIDS 1996; 4: 1-4.
176. Altman L. Scientists display
substantial gains in AIDS treatment. New York Times (New York) 1996:
1A, July 11.
177. Wei X, Ghosh SK, Taylor ME,
Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn
BH, Saag MS, Shaw GM. Viral dynamics in human immunodeficiency virus type
1 infection. Nature 1995; 373: 117-122.
178. Wain-Hobson S. Virological mayhem.
Nature 1995; 373: 102.
179. Duesberg PH, Schwartz JR. Latent
viruses and mutated oncogenes: no evidence for pathogenicity. Progress
in Nucleic Acid Research and Molecular Biology 1992; 43: 135-204.
180. Tanaka M. Abrams cautious on
use of new AIDS drugs. Synapse 1996; 41: 1,5.
181. Continuum. Drugs Boost. Continuum
1996; 4: 3, July/August.
182. Selik RM, Buehler JW, Karon
JM, Chamberland ME, Berkelman RL. Impact of the 1987 revision of the case
definition of acquired immune deficiency syndrome in the United States.
J AIDS 1990; 3: 73-82.
183. Darby SC, Ewart DW, Giangrande
PLF, Dolin PJ, Spooner RJD, Rizza CR, on behalf of the UK Haemophilia Centre
Directors' Organisation. Mortality before and after HIV infection in the
complete UK population of haemophiliacs (letter). Nature 1995; 377:
79-82.
184. The Lancet. Zidovudine for mother,
fetus, and child: hope or poison? Lancet 1994; 344: 207-209.
185. Cotton P. Trial Halted After
Drug Cuts Maternal HIV Transmission Rate By Two Thirds. JAMA 1994;
271: 807.
186. Gill PS, Harrington WJ, Kaplan
MH, Ribeiro RC, Bennett JM, Liebmann HA, Bernstein-Singer M, Espina BM,
Cabral L, Allen S, et al. Treatment of adult T-cell leukemia-lymphoma with
a combination of interferon alfa and zidovudine. NEJM 1995; 332:
1744-1748.
187. Continuum. Clever drug or is
it the marketing? Continuum 1995; 3: 2, November/December.
188. Potts M. Non-surgical abortion:
who's for methotrexate. Lancet 1995; 346: 655-656.
189. Bethell T. The Cure that Failed.
National Review 1993; 33-36, May 10.
190. Greenblatt RM, Hollander H,
McMaster JR, Henke CJ. Polypharmacy among patients attending an AIDS clinic:
utilization of prescribed, unorthodox, and investigational treatments.
Journal of Acquired Immune Deficiency Syndromes 1991; 4:
136-143.
191. Kramer L. Checking in, my chart.
POZ 1994; 92-93, August/September.
192. Tuller D. Uncertain life after
certain death. San Francisco Chronicle (San Francisco) 1996: 1-5
zone 6, November 24.
193. Grubman S, Gross E, Lerner-Weiss
N, Hernandez M, McSherry GD, Hoyt LG, Boland M, Oleske JM. Older Children
and Adolescents Living with Perinatally Acquired Human Immunodeficiency
Virus Infection. Pediatrics 1995; 95: 657-663.
194. Merck Research Laboratories.
The Merck Manual of Diagnosis and Therapy. Merck & Co., Inc., Rahway,
NJ, 1992.
195. Freiman JP, Helfert KE, Hamrell
MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients.
AIDS 1993; 7: 379-385.
196. McLeod GX, Hammer SM. Zidovudine:
Five Years Later. Annals of Internal Medicine 1992; 117:
487-501.
197. Parker WB, Cheng YC. Mitochondrial
Toxicity of Antiviral Nucleoside Analogs. The Journal of NIH Research
1994; 6: 57-61.
198. Pluda JM, Yarchoan R, Jaffe
ES, Feuerstein IM, Solomon D, Steinberg S, Wyvill KM, Raubitschek A, Katz
D, Broder S. Development of non-Hodgkin lymphoma in a cohort of patients
with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral
therapy. Ann Intern Med 1990; 113: 276-282.
199. Aboulker J-P, Swart AM. Preliminary
analysis of the Concorde trial. The Lancet 1993; 341: 889-890.
200. Kumar RM, Hughes PF, Khurranna
A. Zidovudine Use in Pregnancy: A Report on 104 Cases and the Occurence
of Birth Defects. Journal of Acquired Immune Deficiency Syndromes
1994; 7: 1034-1039.
201. Saah AJ, Hoover
DR, Peng Y, Phair JP, Visscher B, Kingsley LA, Schrager LK, for the Multicenter
AIDS Cohort Study. Predictors for failure of Pneumocystis carinii pneumonia
prophylaxis. JAMA 1995; 273: 1197-1202.
202. Lenderking WR, Gelber RD, Cotton
DJ, Cole BF, Goldhirsch A, Volberding PA, Testa MA. Evaluation of the quality
of life associated with Zidovudine treatment in asymptomatic Human Immunodeficiency
Virus infection. N Engl J Med 1994; 330: 738-743.
203. Poznansky MC, Coker R, Skinner
C, Hill A, Bailey S, Whitaker L, Renton A, Weber J. HIV positive patients
first presenting with an AIDS defining illness: characteristics and survival.
British Medical Journal 1995; 311: 156-158.
204. Goedert JJ, Cohen AR, Kessler
CM, Eichinger S, Seremetis SV, Rabkin CS, Yellin FJ, Rosenberg PS, Aledort
LM. Risks of immunodeficiency, AIDS, and death related to purity of factor
VIII concentrate. Lancet 1994; 344: 791-792.
205. Moye J, Rich KC, Kalish LA,
Sheon AR, Diaz C, Cooper ER, Pitt J, Handelsman E, for the Women and Infants
Transmission Study Group. Natural history of somatic growth in infants
born to women infected by human immunodeficiency virus. The Journal
of Pediatrics 1996; 128: 58-67.
206. Pennisi E, Cohen J. Eradicating
HIV from a patient: not just a dream? Science 1996; 272:
1884.
207. Douglas RGJ. Antimicrobial Agents,
in The Pharmacological Basis of Therapeutics, Alfred, Goodman, Gilman
and et al. (eds.) Pergamon Press, New York, 1990; 1182.
208. Jacobson MA, de Miranda P, Gordon
SM, et al. Prolonged pancytopenia due to combined ganciclovir and zidovuduine
therapy. J Infect Dis 1988; 158: 489-490.
209. Fogelman I, Lim L, Bassett R,
Volberding P, Fischl MA, Stanley K, Cotton DJ, for the AIDS Clinical Trials
Group. Prevalence and patterns of use of concomitant medications among
participants in three multicenter human immunodeficiency virus type 1 clinical
trials. Journal of Acquired Immune Deficiency Syndromes 1994; 7:
1057-1063.
210. Leland J. The end of AIDS? Newsweek
1996; 64-73, December 2.
211. Ottoboni A. Dose makes the poison.
Van Nostrand & Reingold/ Int. Tompson Publishing, 1991.
212. Fenner F, McAuslan BR, Mims
CA, Sambrook J, White DO. The Biology of Animal Viruses. Academic Press,
Inc., New York, 1974.
213. Krieger T, Caceres CA. Wall
Street Journal 1985: October 24.
214. Mathur-Wagh U, Enlow RW, Spigland
I, Winchester RJ, Sacks HS, Rorat E, Yancovitz SR, Klein MJ, William DC,
Mildwan D. Longitudinal study of persistent generalized lymphadenopathy
in homosexual men: Relation to acquired immunodeficiency syndrome. Lancet
1984; i: 1033-1038.
215. Marmor M, Friedman-Kien AE,
Laubenstein L, Byrum RD, William DC, D'Onofrio S, Dubin N. Risk factors
for Kaposi's sarcoma in homosexual men. Lancet 1982; i: 1083-1087.
216. Newell GR, Mansell PWA, Wilson
MB, Lynch HK, Spitz MR, Hersh EM. Risk factor analysis among men referred
for possible acquired immune deficiency syndrome. Preventive Med
1985; 14: 81-91.
217. Haverkos HW, Pinsky PF, Drotman
DP, Bregman DJ. Disease manifestation among homosexual men with acquired
immunodeficiency syndrome: a possible role of nitrites in Kaposi's sarcoma.
J Sex Trans Dis 1985; 12: 203-208.
218. Rappoport J. AIDS INC. Human
Energy Press, San Bruno, CA, 1988.
219. Fettner AG, Check WA. The Truth
about AIDS: Evolution of an Epidemic. Holt, Rinehart and Wilson, New York,
1985.
220. Oppenheimer GM. Causes, cases,
and cohorts: The role of epidemiology in the historical construction of
AIDS, in AIDS: The Making of a Chronic Disease, E. Fee and D. M.
Fox (eds.) University of California Press, Berkeley, 1992; 49-83.
221. Lang S. HIV and AIDS: Have we
been misled? Questions of scientific and journalistic resposibility, in
AIDS: virus or drug-induced?, P. Duesberg (eds.) Kluwer, Academic
publishers, Dordrecht, The Netherlands/Boston/London, 1996; 241-270.
222. Craddock M. A critical appraisal
of the Vancouver men's study; does it refute the drugs/AIDS hypothesis?,
in AIDS: virus or drug-induced, P. H. Duesberg (eds.) Kluwer Academic
Publishers, Dordrecht, Netherland, 1996; 105-110.
223. Duesberg P. Aetiology of AIDS.
Lancet 1993; 341: 1544.
224. Centers for Disease Control.
Update: Outbreak of Ebola viral hemorrhagic fever Zaire, 1995. Morb
Mort Weekly Reports 1995; 44: 399.
225. Duesberg P. The Duesberg-Phenomenon:
Duesberg and Other Voices (letter). Science 1995; 267: 313.
226. Ward JW, Bush TJ, Perkins HA,
Lieb LE, Allen JR, Goldfinger D, Samson SM, Pepkowitz SH, Fernando LP,
Holland PV, Kleinman SH, Grindon AJ, Garner JL, Rutherford GW, Holmberg
SD. The natural history of transfusion-associated infection with human
immunodeficiency virus. N Engl J Med 1989; 321: 947-952.
227. Centers for Disease Control
and Prevention. U.S. HIV and AIDS cases reported through June 1994, Mid-Year
Edition. HIV/AIDS Surveillance Report 1994; 6: 1-27.
228. Centers for Disease Control.
Update: acquired immunodeficiency syndrome—United States. Morbidity
and Mortality Weekly Reports 1985; 34: 245-248.
229. Haverkos HW, Drotman DP. Measuring
inhalant nitrite exposure in gay men: implications for elucidating the
etiology of AIDS-related Kaposi's sarcoma. Genetica 1995; 95:
157-164.
230. National Institute on Drug Abuse.
Annual Emergency Room Data 1990. 1990;
231. Mok JQ, De Rossi A, Ades AE,
Giaquinto C, Grosch-Woerner I, Peckham CS. Infants born to mothers seropositive
for human immunodeficiency virus. Lancet 1987; i: 1164-1168.
232. European Collaborative Study.
Children born to women with HIV-1 infection: natural history and risk of
transmission. Lancet 1991; 337: 253-260.
233. Rodriguez EM, Mofenson LM, Chang
B-H, Rich KC, Fowler MG, Smeriglio V, Landesman S, Fox HE, Diaz C, Green
K, Hanson IC, for the Women and Infants Transmission Study. Association
of maternal drug use during pregnancy with maternal HIV culture positivity
and perinatal HIV transmission. AIDS 1996; 10: 273-282.
234. Irwin DH, Kaplan LD. Pulmonary
manifestations of acquired immunodeficiency syndrome-associated malignancies.
Seminars in Respiratory Infections 1993; 8: 139-148.
235. Gill PS, Akli B, Coletti P,
Rarick M, Louriero C, Bernstein-Singer M, Krailo M, M. LA. Pulmonary Kaposi's
sarcoma: clinical findings and results of therapy. Am J Med 1989;
87: 57-61.
236. Meduri GU, Stover DE, Lee M,
Myskowski PL, Caravelli JF, Zama MB. Pulmonary Kaposi's sarcoma in the
acquired immune deficiency syndrome: clinical, radiographic, and pathologic
manifestations. Am J Med 1986; 81: 11-18.
237. Sloand E, Kumar PN, Pierce PF.
Chemotherapy for patients with pulmonary Kaposi's sarcoma: benefit of filgrastim
(G-CSF) in supporting dose administration. Southern Medical Journal
1993; 86: 1219-1224.
238. Garay SM, Belenko M, Fazzini
E, Schinella R. Pulmonary manifestations of Kaposi's sarcoma. Chest
1987; 91: 39-43.
239. Kaposi M. Idiopathisches multiples
Pigmentsarkom der Haut. Archiv für Dermatologie und Syphilis
1872; 2: 265-273.
240. Drotman DP, Haverkos H. What
Causes Kaposi's Sarcoma? Inquiring Epidemiologists Want to Know. Epidemiology
1992; 3: 191-193.
241. Toufexis A. Innocent victims.
Time 1991; 137: 56-60,
242. Schuster CR. Foreword, in Cocaine:
Pharmacology, Effects and Treatment of Abuse, J. Grabowski (eds.) National
Institute on Drug Abuse, Washington, DC, 1984; VII-VIII.
243. Savona S, Nardi MA, Lenette
ET, Karpatkin S. Thrombocytopenic purpura in narcotics addicts. Ann
Intern Med 1985; 102: 737-741.
244. Donahoe RM, Bueso-Ramos C, Donahoe
F, Madden JJ, Falek A, Nicholson JKA, Bokos P. Mechanistic implications
of the findings that opiates and other drugs of abuse moderate T-cell surface
receptors and antigenic markers. Annals of the New York Academy of Sciences
1987; 496: 711-721.
245. Espinoza P, Bouchard I, Buffet
C, Thiers V, Pillot J, Etienne JP. High prevalence of infection by hepatitis
B virus and HIV in incarcerated French drug addicts. Gastroenterologie
Clinique et Biologique 1987; 11: 288-292.
246. Weber R, Ledergerber W, Opravil
M, Siegenthaler W, Lüthy R. Progression of HIV infection in misusers
of injected drugs who stop injecting or follow a programme of maintenance
treatment with methadone. Br Med J 1990; 301: 1362-1365.
247. Associated Press. Study Finds
Ex-Smokers Still Risk Lung Cancer. San Francisco Chronicle (San
Francisco) 1995: A5, May 23.
248. Cohen J. New clues found to
how some people live with HIV. Science 1995; 270: 917-918.
249. Learmont J, Tindall B, Evans
L, Cunningham A, Cunningham P, Wells J, Penny R, Kaldor J, Cooper DA. Long-term
symptomless HIV-1 infection in recipients of blood products from a single
donor. Lancet 1992; 340: 863-867.
250. McCarthy M. Attenuated HIV-1
strains share gene deletyions. Lancet 1995; 346: 1357.
251. Cao Y, Quin L, Zhang L, Safrit
J, Ho DD. Virologic and Immunologic Characterization of Long-Term Survivors
of Human Immunodeficiency Virus Type 1 Infection. N Engl J Med 1995;
332: 201-208.
252. Munoz A. Disease progression
15 percent of HIV-infected men will be long-term survivors. AIDS Weekly,
(News Report) 1995; May, 15 & 29: 5-6 & 3-4.
253. Gavzer B. Love has Helped Keep
me Alive. Parade Magazine 1995; 4-6, April 16.
254. Wells J. We have to question
the so-called 'facts'. Capital Gay 1993: 14-15, August 20th.
255. Root-Bernstein RS. Five myths
about AIDS that have misdirected research and treatment. Genetica
1995; 95: 111-132.
256. Callen M. Surviving AIDS. HarperPerennial,
New York, 1990.
257. Gorman C. Time 1993;
49, 22 March.
258. Pantaleo G, Menzo S, Vaccarezza
M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C,
Schrager LK, et al. Studies in subjects with long-term nonprogressive human
immunodeficiency virus infection. N Engl J Med 1995; 332:
209-216.
259. Munoz A, Kirby AJ, He YD, Margolick
JB, Visscher BR, Rinaldo CR, Kaslow RA, Phair JP. Long-term survivors with
HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
1995; 8: 496-505.
260. Hoover DR, Rinaldo C, He Y,
Phair J, Fahey J, Graham NM. Long-term survival without clinical AIDS after
CD4+ cell counts fall below 200 x 10 (6)/1. AIDS 1995; 9:
145-152.
261. Hogervorst E, Jurriaans S, De
Wolf F, Van Wijk A, Wiersma A, Valk M, Roos M, Van Gemen B, Coutinho R,
Miedema F, et al. Predictors for non- and slow progression in human immunodeficiency
virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance
of high HIV-1 p24-specific but not V3-specific antibody levels. Journal
of Infectious Diseases 1995; 171: 811-821.
262. Montefiori DC, Pantaleo G, Fink
LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS. Neutralizing and
infection-enhancing antibody responses to human immunodeficiency virus
type 1 in long-term nonprogressors. Journal of Infectious Diseases
1996; 173: 60-67.
263. Harrer T, Harrer E, Kalams SA,
Elbeik T, Staprans SI, Feinberg MB, Cao Y, Ho DD, Yilma T, Caliendo AM,
et al. Strong cytotoxic T cell and weak neutralizing antibody responses
in a subset of persons with stable nonprogressing HIV type 1 infection.
Aids Research and Human Retroviruses 1996; 12: 585-592.
264. Garbulgia AR, Salvi R, Dicaro
A, Cappiello G, et al. In vitro activation of HIV RNA expression in peripheral
blood lymphocytes as a marker to predict the stability of non-progressor
status in long-term survivors. AIDS 1996; 10: 17-21.
265. Baltimore D. Lessons from people
with nonprogressive HIV infection (editorial; comment). N Engl J Med
1995; 332: 259-260.
266. Hand TH. Antiviral Drugs versus
Long-Term Survival; Why antiviral drugs cannot resolve AIDS. Reappraising
AIDS 1996; 4: 1-4.
267. Maddox J. Rage and confusion
hide role of HIV. Nature 1992; 357: 188-189.
268. Simmons T. Living on the edge.
The Advocate 1995; December: 25-28, December 26.
269. Merson MH. Slowing the spread
of HIV: Agenda for the 1990's. Science 1993; 260: 1266-1268.
270. World Health Organization. The
current Global Situation of the HIV/AIDS Pandemic. 1995;
271. Strathdee SA, Craib KJP, Hogg
RS, M. OS, Montaner J, Schechter MT. Long-term non-progression in HIV infection.
Lancet 1995; 346: 1372.
272. Cocchi F, DeVico A, Grazino-Demo
A, Arya SK, Gallo RC, Lusso P. Identification of Rabntes, Mip-1a, and Mip-1b
as the major HIV-suppressive factors produced by CD8+ T cells. Science
1995; 270: 1811-1815.
273. Lang W, Perkins H, Anderson
RE, Royce R, Jewell N, Winkelstein W, Jr. Patterns of T lymphocyte changes
with human immunodeficiency virus infection: from seroconversion to the
development of AIDS. JAIDS 1989; 2: 63-69.
274. Lang W, Anderson RE, Perkins
H, Grant RM, Lyman D, Winkelstein W, Royce R, Levy JA. Clinical, Immunologic,
and Serologic Findings in Men at Risk for Acquired Immunodeficiency Syndrome.
JAMA 1987; 257: 326-330.
275. Ellison BJ, Downey AB, Duesberg
PH. HIV as a surrogate marker for drug-use: a re-analysis of the San Francisco
Men's Health Study. Genetica 1995; 95: 165-171.
276. Marion SA, Schechter MT, Weaver
MS, McLeod WA, Boyko WJ, Willoughby B, Douglas B, Craib KJP, O'Shaughnessy
M. Evidence that prior immune dysfunction predisposes to human immunodeficiency
virus infection in homosexual men. JAIDS 1989; 2: 178-186.
277. Archibald CP, Schechter MT,
Le TN, Craib KJP, Montaner JSG, O'Shaughnessy MV. Evidence for a sexually
transmitted cofactor for AIDS-related Kaposi's sarcoma in a cohort of homosexual
men. Epidemiology 1992; 3: 203-209.
278. Kaslow RA, Phair JP, Freidman
HB, Lyter RE, Solomon RE, Dudley J, Polk F, Blackwelder W. Infection with
the Human Immunodeficiency Virus: clinical manifestations and their relationship
to immunodeficiency. Ann Intern Med 1987; 107: 474-480.
279. Ostrow DG, Van Raden MJ, Fox
R, Kingsley LA, Dudley J, Kaslow RA, the Multicenter AIDS Cohort Study
(MACS). Recreational drug use and sexual behavior change in a cohort of
homosexual men. AIDS 1990; 4: 759-765.
280. Phair J, Jacobson L, Detels
R, Rinaldo C, Saah A, Schrager L, Munoz A. Acquired immune deficiency syndrome
occuring within 5 years of infection with human immunodeficiency virus
type-1: The multicenter AIDS cohort study. J Acquired Immune Deficiency
Syndromes 1992; 5: 490-496.
281. Parke D. Key factor. The
Sunday Times (London) 1993: letter, Dec. 19.
282. Seidman SN, Rieder RO. A Review
of Sexual Behaviour in the United States. The American Journal of Psychiatry
1994; 151: 330-341.
283. Des Jarlais DC, Friedman SR,
Marmor M, Mildvan D, Yancovitz S, Sotheran JL, Wenston J, Beatrice S. CD4
Lymphocytopenia among injecting drug users in New York City. J Acquir
Immune Defic Syndr 1993; 6: 820-822.
284. Nicolosi A, Musico M, Saracco
A, Molinari S, Ziliani N, Lazzarin A. Incidence and risk factors of HIV
infection: A prospective study of seronegative drug users from Milan and
Northern Italy, 1987-1989. Epidemiology 1990; 1: 453-459.
285. Moore PS, Chang Y. Detection
of Herpesvirus-like DNA Sequences in Kaposi's Sarcoma in Patients With
and Those Without HIV Infection. N Engl J Med 1995; 332:
1181-1185.
286. Weiss SH, Weston Klein C, Mayur
RK, Besra J, Denny TN. Idiopathic CD4+ T-lymphocytopenia. Lancet
1992; 340: 608-609.
287. Gottlieb MS, Schanker HM, Fan
PT, Saxon A, Weisman JD, Pozalski J. Pneumocystis pneumonia—Los Angeles.
Morbidity and Mortality Weekly Reports 1981; 30: 250-252.
288. Haverkos HW. Kaposi's sarcoma
and nitrite inhalants, in Psychological, Neuropsychiatric and Substance
Abuse Aspects of AIDS, T. P. Bridge, H. Heather and M. Johnson (eds.)
Raven Press, New York, 1988; 165-172.
289. van Griensven GJP, Vroome EMM,
de Wolf H, Goudsmit J, Roos M, Coutinho RA. Risk factors for progression
of human immunodeficiency virus (HIV) infection among seroconverted and
seropositive homosexual men. Am J Epidemiol 1990; 132: 203-210.
290. Graham NMH, Zeger SL, Park LP,
Phair JP, Detels R, Vermund SH, Ho M, Saah AJ, Multicenter AIDS Cohort
Study. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis
on progression of HIV-1 infection to AIDS. Lancet 1991; 338:
265-269.
291. Seage GR, Mayer KH, Horsburgh
CR, Holmberg SD, Moon MW, Lamb GA. The relation between nitrite inhalants,
unprotected receptive anal intercourse, and the risk of human immunodeficiency
virus infection. J Am Epidemiol 1992; 135: 1-11.
292. Winkelstein W, Jr., Lyman DH,
Padian N, Grant R, Samuel M, Wiley JA, Anderson RE, Lang W, Riggs J, Levy
JA. Sexual practices and risk of infection by the human immunodeficiency
virus: The San Francisco men's health study. JAMA 1987; 257:
321-325.
293. Lemp GF, Payne SF, Rutherford
GW, Hessol NA, Winkelstein W, Jr., Wiley JA, Moss AR, Chaisson RE, Chen
RT, Feigal DW, Thomas PA, Werdegar D. Projections of AIDS morbidity and
mortality in San Francisco. J Am Med Assoc 1990; 263: 1497-1501.
294. Mathur-Wagh U, Mildvan D, Senie
RT. Follow-up of 4 1/2 years on homosexual men with generalized lymphadenopathy.
NEJM 1985; 313: 1542-1543.
295. San Francisco Department of
Public Health, Lesbian & Gay Substance Abuse Planning Group. Gay Men,
Lesbians and their Alcohol and Other Drug Use: A Review of the Literature.
1991 September;
296. Selik RM, Starcher ET, Curran
JW. Opportunistic diseases reported in AIDS patients: frequencies, associations,
and trends. AIDS 1987; 1: 175-182.
297. Friedman-Kien AE, Saltzman BR,
Cao Y, Nestor MS, Mirabile M, Li JJ, Peterman TA. Kaposi's sarcoma in HIV-negative
homosexual men. Lancet 1990; 335: 168-169.
298. Safai B, Peralta H, Menzies
K, Tizon H, Roy P, Flomberg N, Wolinsky S. Kaposi's sarcoma among HIV-negative
high risk population. VII International Conference on AIDS. 1991;
299. Anonymous. Patient accuses Kaiser.
Oakland Tribune 1992; December 1.
300. Papadopulos-Eleopulos E, Turner
VF, Papadimitriou JM. Is a positive Western blot proof of HIV infection?
Biotechnology 1993; 11: 696-707.
301. Johnson, C., Zenger's magazine,
California. Sept. 1996. Factors known to cause false-positie HIV antibody
test results. Continuum (London) 1996; 4: 5,
302. Cohen J. Is a new virus the
cause of KS? Science 1994; 266: 1803-1804.
303. Ascher MS, Sheppard HW, Winkelstein
Jr. W. AIDS-associated Kaposi's sarcoma (letter). Science 1995;
267: 1080.
304. Selwyn PA, Feingold AR, Hartel
D, Schoenbaum EE, Adderman MH, Klein RS, Freidland SH. Increased risk of
bacterial pneumonia in HIV-infected intravenous drug users without AIDS.
AIDS 1988; 2: 267-272.
305. Braun MM, Truman BI, Maguire
B, Di Ferdinando GT, Jr., Wormser G, Broaddus R, Morse DL. Increasing incidence
of tuberculosis in a prison inmate population, associated with HIV-infection.
J Am Med Assoc 1989; 261: 393-397.
306. Centers for Disease Control.
Revision of the CDC surveillance case definition for acquired immunodeficiency
syndrome. JAMA 1987; 258: 1143-1154.
307. Annell A, Fugelstad A, Ågren
G. HIV-prevalence and mortality in relation to type of drug abuse among
drug addicts in Stockholm 1981-1988, in Drug Addiction and AIDS,
N. Loimer, R. Schmid and A. Springer (eds.) Springer-Verlag, New York,
1991; 16-22.
308. Püschel K, Mohsenian F.
HIV-1-prevalence among drug deaths in Germany, in Drug Addiction and
AIDS, N. Loimer, R. Schmid and A. Springer (eds.) Springer-Verlag,
New York, 1991; 89-96.
309. Bschor F, Bornemann R, Borowski
C, Schneider V. Monitoring of HIV-spread in regional populations of injecting
drug users—the Berlin experience, in Drug Addiction and AIDS, N.
Loimer, R. Schmid and A. Springer (eds.) Springer-Verlag, New York, 1991;
102-109.
310. Mientjes GH, Miedema F, van
Ameijden EJ, van den Hoek AA, Schellekens PTA, Roos MT, Coutinho RA. Frequent
injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative
drug users. AIDS 1991; 5: 35-41.
311. Des Jarlais DC, Friedman SR,
Hopkins W. Risk reduction of the acquired immunodeficiency syndrome among
intravenous drug users, in AIDS and IV Drug Abusers: Current Perspectives,
R. P. Galea, B. F. Lewis and L. Baker (eds.) National Health Publishing,
Owings Mills, MD, 1988; 97-109.
312. Brudney K, Dobkin J. Resurgent
tuberculosis in New York City. Am Rev Respir Dis 1991; 144:
744-749.
313. Koch T. Uninfected children
of HIV-infected mothers may still suffer nervous problems. CDC AIDS
Weekly 1990; 9, July 30.
314. Aylward EH, Butz AM, Hutton
N, Joyner ML, Vogelhut JW. Cognitive and motor development in infants at
risk for human immunodeficiency virus. AJDC 1992; 146: 218-222.
315. Rogers MF, Ou C-Y, Rayfield
M, Thomas PA, Schoenbaum EE, Abrams E, Krasinski K, Selwyn PA, Moore J,
Kaul A, Grimm KT, Bamji M, Schochetman G, the New York City Collaborative
Study of Maternal HIV Transmission, Montefiori Medical Center HIV Perinatal
Transmission Study Group. Use of the polymerase chain reaction for early
detection of the proviral sequences of human immunodeficiency virus in
infants born to seropositive mothers. NEJM 1989; 320: 1649-1654.
316. Culver KW, Ammann AJ, Patridge
JC, Wong DF, Wara DW, Cowan MJ. Lymphocyte abnormalities in infants born
to drug-abusing mothers. J Pediatr 1987; 111: 230-235.
317. Scolaro M, Durham R, Pieczenik
G. Potential molecular competitor for HIV. Lancet 1991; 337:
731-732.
318. Till M, MacDonnell KB. Myopathy
with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine?
Ann Intern Med 1990; 113: 492-494.
319. Gill PS, Rarick M, Byrnes RK,
Causey D, Loureiro C, Levine AM. Azidothymidine associated with bone marrow
failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern
Med 1987; 107: 502-505.
320. Freeman E. HIV does not cause
AIDS. HealthQuest 1996; 35-49, Fall 1996.
321. Hughes MD, Stein DS, Gundacker
HM, Valentine FT, Phair JP, Volberding PA. Within-Subject Variation in
CD4 Lymphocyte Count in Asymptomatic Human Immunodeficiency Virus Infection:
Implications for Patient Monitoring. J Infectious Diseases 1994;
169: 28-36.
322. Blanche S, Mayaux M-J, Rouzioux
C, Teglas J-P, Firtion G, Monpoux F, Ciraru-Vigneron N, Meier F, Tricoire
J, Courpotin C, Vilmer E, Griscelli C, Delfraissy J-F, The French Pediatric
HIV Infection Study Group. Relation of the Course of HIV Infection in Children
to the Severity of the Disease in their Mothers at Delivery. The New
England Journal of Medicine 1994; 330: 308-312.
323. The European Collaborative Study.
Natural History of Vertically Acquired Human Immunodeficiency Virus-1 Infection.
Pediatrics 1994; 94: 815-819.
324. Friedman SR, Jose B, Deren S,
Des Jarlais DC, Neaigus A. Risk Factors for Human Immunodeficiency Virus
Seroconversion among Out-of-Treatment Drug Injectors in High and Low Seroprevalence
Cities. American Journal of Epidemiology 1995; 142: 864-874.
325. Evenson W. Heroin's in fashion
- and death statistics prove it. San Francisco Chronicle (San Francisco)
1996: A1, A8, July 30.
326. Centers for Disease Control
and Prevention. U.S. HIV and AIDS cases reported through June 1996. HIV/AIDS
Surveillance Report 1996; 8: 1-33.
327. Kramer A. HIV hits former USSR
a small city's story. San Francisco Chronicle (San Francisco)
1996: A1 & A11, November 26.
328. Gallo RC, Sarin PS, Gelmann
EP, Robert-Guroff M, Richardson E. Isolation of human T-cell leukemia virus
in acquired immune deficiency syndrome (AIDS). Science 1983; 220:
865-867.
329. Montagnier L, Chermann JC, Barré-Sinoussi
F, Chamaret S, Gruest J, Nugeyre MT, Rey F, Dauguet C, Axler-Blin C, Vézinet-Brun
F, Rouzioux C, Saimot G-A, Rozenbaum W, Gluckman JC, Klatzmann D, Vilmer
E, Griscelli C, Foyer-Gazengel C, Brunet JB. A new human T-lymphotropic
retrovirus: Characterization and possible role in lymphadenopathy and acquired
immune deficiency syndromes, in Human T-Cell Leukemia/Lymphona Virus;
The Family of Human T-Lymphotropic Retroviruses: Their Role in Malignancies
and Association with AIDS, R. C. Gallo, M. E. Essex and L. Gross (eds.)
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1984; 363-379.
330. Centers for Disease Control.
An evaluation of the immunotoxic potential of isobutyl nitrite. MMWR
1983; 32: 457-464.
331. McKeown T. The Role of Medicine:
Dream, Mirage, or Nemesis? Princeton University Press, Princeton, NJ, 1979.
332. Kolata G. Anthropologists suggest
cannibalism is a myth. Science 1986; 232: 1497-1500.
333. Stolberg S. Studies rebut controversial
AIDS theory. Los Angeles Times (Los Angeles) 1993: A18, March 11.
334. Perlman D. Biologist's theory
on AIDS attacked. San Francisco Chronicle (San Francisco) 1993:
A10, March 11.
335. Duesberg P. HIV and the aetiology
of AIDS. Lancet 1993; 341: 957-958.
336. Duesberg P. AIDS Data. Science
1995; 268: 350-351.
337. Ascher M, Sheppard HW, Winkelstein
W. AIDS Data. Science 1995; 268: 351-352.
338. Klimas NG, Blaney NT, Morgan
RO, Chitwood D, Milles K, Lee H, Fletcher MA. Immune Function and Anti-HTLV-I/II
Status in Anti-HIV-1-Negative Intravenous Drug Users Receiving Methadone.
The American Journal of Medicine 1991; 90: 163-170.
339. Schechter MT, Craib KJP, Gelmon
KA, Montaner JSG, Le TN, O'Shaughnessy MV. HIV-1 and the aetiology of AIDS.
Lancet 1993; 341: 658-659.
340. Smith GD, Phillips AN. Confounding
in epidemiological studies: why independent effects may not be all they
seem. BMJ 1992; 305: 757-759.
341. Maddox J. Has Duesberg a right
of reply? Nature 1993; 363: 109.
342. Koliadin V. Duesberg: rights
and wrongs. Nature 1993; 364: 96.
343. Birkett N. The Duesberg phenomenon:
Duesberg and other voices. Science 1995; 268: 315.
344. Farber C. AIDS Words from
the Front. SPIN Magazine 1995; 189-193, 214-215, April.
345. Ostrom N. Early Intervention:
An Idea Whose Time Has Gone? New York Native 1995; 35-39, August
28.
346. Ostrom N. Nightmare on AZT Street.
New York Native 1995; 34-36, September 4.
347. Duesberg P. Duesberg responds
(letter). The Scientist 1995: 13, September 4.
348. Kolata G. Debunking doubts that
HIV causes AIDS. The New York Times (New York) 1993: A11, March
11.
349. Gutknecht G. Letter to Dr. Fauci.
(Washington, D.C.) 1995: March 24.
350. AIDS Weekly. Government Congressman
questions funding for AIDS research. AIDS Weekly (electronic version)
1995; May, 22:
351. Chronicle SF. California winning
war on cigarette smoking. San Francisco Chronicle (San Francisco)
1996: A3, Nov. 8, 1996.
352. McCormack TP. The AIDS benefits
handbook: everything you need to know to get social security, welfare,
medicaid, medicare, food stamps, housing, drugs, and other benefits. Yale
University Press, New Haven, 1990.